Imagine a vaccine that's already passed the big tests but needs a push to reach people in the hardest-hit areas. This work helps move that vaccine into countries like Brazil and makes sure it's safe for kids and pregnant women. It also sets up a global network to test how new coronavirus vaccines can stop a virus from spreading from person to person.
Existing Chikungunya vaccines lack sufficient data for use in vulnerable populations and limited manufacturing capacity prevents access in low-income countries.
A technology transfer mechanism for vaccine production and a global network of experts for Controlled Human Infection Models (CHIM).
If you are a vaccine producer dealing with limited production capacity for tropical diseases — this project developed a technology transfer path for the Valneva vaccine that allows additional manufacturers to expand access in Asian low- and middle-income countries.
If you are a CRO dealing with the need for high-reliability human infection data — this project developed a global network of experts conducting Controlled Human Infection Models (CHIM) to advance transmission-blocking vaccines.
If you are a health agency dealing with 480,000 reported Chikungunya cases in 2024 — this project developed Phase IV clinical trial data to support the use of vaccines in vulnerable populations like children and pregnant women.
The project leverages EUR 70,000,000 from Horizon Europe, supplemented by EUR 30,000,000 from CEPI, totaling EUR 100,000,000.
The project enables technology transfer of the vaccine drug product to an additional vaccine manufacturer to accelerate access in Asian low- and middle-income countries.
The vaccine developed by Valneva has already been approved by the US FDA, Health Canada, and European EMA; the project now supports its licensure in Brazil.
The project focuses on Phase IV clinical trials to understand long-term safety and effectiveness, as well as extending use indications for children, immunosuppressed, and pregnant women.
The project period runs from 2023-06-01 to 2028-11-30, with individual awards lasting 36–48 months.
The project is coordinated by a single entity, the Coalition for Epidemic Preparedness Innovations (CEPI), acting as a funding and administrative hub. While the consortium data shows 1 partner, the project operates as a grant-making mechanism, distributing EUR 100 million to various vaccine manufacturers and research networks globally.
Contact the CEPI secretariat regarding the Call for Proposals on CHIM.
Contact us to identify potential vaccine manufacturing partners for technology transfer.
